Lynn Seely - 15 Dec 2022 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Role
President and CEO, Director
Signature
/s/ Charles Newton, as Attorney-in-Fact
Issuer symbol
LYEL
Transactions as of
15 Dec 2022
Net transactions value
$0
Form type
4
Filing time
19 Dec 2022, 15:20:33 UTC
Previous filing
30 Jun 2022
Next filing
23 Jun 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LYEL Option (right to buy) Award $0 +7,500,000 $0.000000 7,500,000 15 Dec 2022 Common Stock 7,500,000 $3.28 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Twenty-five (25) percent of the shares subject to the option shall vest on December 15, 2023 and 1/48th of the shares subject to the option shall vest in equal monthly installments thereafter until all shares are vested, subject to the reporting person remaining an employee of the Issuer on each applicable vesting date.